These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25805800)

  • 1. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
    Peeters SG; Zegers CM; Biemans R; Lieuwes NG; van Stiphout RG; Yaromina A; Sun JD; Hart CP; Windhorst AD; van Elmpt W; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Jul; 21(13):2984-92. PubMed ID: 25805800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging.
    Dubois LJ; Lieuwes NG; Janssen MH; Peeters WJ; Windhorst AD; Walsh JC; Kolb HC; Ollers MC; Bussink J; van Dongen GA; van der Kogel A; Lambin P
    Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14620-5. PubMed ID: 21873245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the hypoxia PET tracers [¹⁸F]HX4, [¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model.
    Peeters SG; Zegers CM; Lieuwes NG; van Elmpt W; Eriksson J; van Dongen GA; Dubois L; Lambin P
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):351-9. PubMed ID: 25491505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
    Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
    Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters.
    Zegers CM; van Elmpt W; Wierts R; Reymen B; Sharifi H; Öllers MC; Hoebers F; Troost EG; Wanders R; van Baardwijk A; Brans B; Eriksson J; Windhorst B; Mottaghy FM; De Ruysscher D; Lambin P
    Radiother Oncol; 2013 Oct; 109(1):58-64. PubMed ID: 24044790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
    PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume".
    Yaromina A; Granzier M; Biemans R; Lieuwes N; van Elmpt W; Shakirin G; Dubois L; Lambin P
    Radiother Oncol; 2017 Sep; 124(3):513-520. PubMed ID: 28502472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.
    Zegers CM; van Elmpt W; Reymen B; Even AJ; Troost EG; Ollers MC; Hoebers FJ; Houben RM; Eriksson J; Windhorst AD; Mottaghy FM; De Ruysscher D; Lambin P
    Clin Cancer Res; 2014 Dec; 20(24):6389-97. PubMed ID: 25316821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-linear conversion of HX4 uptake for automatic segmentation of hypoxic volumes and dose prescription.
    Ureba A; Lindblom E; Dasu A; Uhrdin J; Even AJG; van Elmpt W; Lambin P; Wersäll P; Toma-Dasu I
    Acta Oncol; 2018 Apr; 57(4):485-490. PubMed ID: 29141489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.
    van Elmpt W; Zegers CML; Reymen B; Even AJG; Dingemans AC; Oellers M; Wildberger JE; Mottaghy FM; Das M; Troost EGC; Lambin P
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):240-248. PubMed ID: 26338178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
    Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
    Trinkaus ME; Blum R; Rischin D; Callahan J; Bressel M; Segard T; Roselt P; Eu P; Binns D; MacManus MP; Ball D; Hicks RJ
    J Med Imaging Radiat Oncol; 2013 Aug; 57(4):475-81. PubMed ID: 23870348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation-An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302.
    Saggar JK; Tannock IF
    Clin Cancer Res; 2015 May; 21(9):2107-14. PubMed ID: 25677696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.
    Lohse I; Rasowski J; Cao P; Pintilie M; Do T; Tsao MS; Hill RP; Hedley DW
    Oncotarget; 2016 Jun; 7(23):33571-80. PubMed ID: 27248663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    De Bruycker S; Vangestel C; Van den Wyngaert T; Pauwels P; Wyffels L; Staelens S; Stroobants S
    J Nucl Med; 2019 Jan; 60(1):34-40. PubMed ID: 29980581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.